Document Detail

Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation.
MedLine Citation:
PMID:  18790199     Owner:  NLM     Status:  MEDLINE    
Alemtuzumab (Campath-1H) is a monoclonal antibody directed against CD52-positive B and T lymphocytes. Initial results of its use as an induction agent in adult renal transplantation have been encouraging. We report a case series of four low-risk pediatric renal transplantation patients who received 20 to 40 mg of alemtuzumab as induction followed by a steroid-free regimen consisting of a calcineurin inhibitor and mycophenolate mofetil. No infusion-related reactions occurred. Patients were aged 9 to 14 years with a mean creatinine of 1.2 mg/dL (range = 0.5-2.3 mg/dL) at a mean follow-up of 10 months (range = 4-16 months). One patient experienced biopsy-proven acute cellular rejections at 4 and 12 months posttransplantation, which were steroid sensitive. Lymphopenia post-alemtuzumab induction started to improve at 3 months posttransplantation. Two patients who received 40 mg of alemtuzumab experienced repeated infections that responded to 7-day courses of antibiotics. There was no cytomegalovirus disease detected. From these preliminary results, alemtuzumab seems to show a promising role to achieve adequate graft function with a steroid-free regimen among low-risk pediatric patients.
E T Ona; R A Danguilan; J Africa; C B Cabanayan-Casasola; Z L Antonio; M A Gutierrez-Marbella; R dela Cruz; N Bumanglag; M E Espedilla
Related Documents :
15009839 - A single center clinical experience in intensive care management of 104 pediatric renal...
15167019 - Pediatric liver transplantation.
11204989 - Effect of variable stiffness colonoscopes on cecal intubation times for routine colonos...
22870789 - Nitric oxide donor drugs improve the distribution and engraftment of transplanted hepat...
23024099 - Etiology and outcome of crescentic glomerulonephritis.
20609169 - Long-term outcomes of pediatric living donor liver transplantation at a single institut...
15261179 - Severe diverticulitis after heart, lung, and heart-lung transplantation.
2671249 - The physical effects of lightning injury.
1862949 - Elastic-like tissue, a new component of the renal glomerular capillary wall in a cartil...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Transplantation proceedings     Volume:  40     ISSN:  0041-1345     ISO Abbreviation:  Transplant. Proc.     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-09-15     Completed Date:  2008-11-12     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0243532     Medline TA:  Transplant Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2226-9     Citation Subset:  IM    
Department of Vascular Surgery, National Kidney and Transplant Institute, Quezon City, Philippines.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / adverse effects,  therapeutic use*
Creatinine / blood
Graft Rejection / parasitology
Histocompatibility Testing
Kidney Failure, Chronic / surgery
Kidney Transplantation / immunology*
Neutropenia / chemically induced
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Neoplasm; 3A189DH42V/alemtuzumab; 60-27-5/Creatinine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.
Next Document:  Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservatio...